弥漫大B细胞淋巴瘤相关微小RNA的研究进展  

Research progress on microRNA related to diffuse large B-cell lymphoma

作　　者：刘林(综述)[1] 张轶文(审校)[1] 张凤(审校)[1] 

机构地区：[1]安徽省蚌埠医学院第一附属医院血液科,233000

出　　处：《白血病．淋巴瘤》2012年第12期763-766,共4页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81071942）;安徽省卫生厅基金（2008B002）

摘　　要：微小RNA（miRNA）是一类长度为20多个核苷酸的内源性非编码调控RNA，通过转录后调控机制来调控基因的表达，参与细胞增殖、分化、代谢、凋亡等一系列重要生物学过程。弥漫大B细胞淋巴瘤（DLBCL）是最常见的一类恶性淋巴瘤，为B细胞起源，侵袭性高、生长迅速，具有显著临床异质性。近年研究发现，若干种miRNA直接参与了DLBCL的发生、发展；miRNA表达谱也与DLBCL分子亚型相关。作为一类新的分子靶标，miRNA在DLBCL的诊断和生物治疗方面具有广阔的应用前景。microRNA （miRNA） is a class of endogenous small non-coding RNA （20-25 nt） which can regulate the expression of protein-coding genes post-transcriptionally and participate in a series of critical biological processes including cell proliferation, differentiation, metabolism, apoptosis, et al. Diffuse large B-cell lymphoma （DLBCL） is the most common lymphoma subtype. DLBCL is defined as the malignant lymphoma which originates from the B cells, with aggressive clinical behaviors and significant clinical heterogeneity. In recent years, the researches on miRNA in DLBCL have shown that several kinds of miRNA directly involved in the occurrence and development of tumors and there is a correlation between the miRNA expression profiles and molecular subtypes of DLBCL. As a kind of new molecular target, miRNA has a broad prospect in the application both for diagnosis and biotherapy of DLBCL.

关 键 词：淋巴瘤 大B-细胞 弥漫眭 微小RNA 分子亚型 诊断 治疗 

分 类 号：R733[医药卫生—肿瘤]